Radiation Research, Vol. 188, No. 2 (August 2017), pp. 156-168 (13 pages) Rapid clinical triage of radiation injury patients is essential for determining appropriate diagnostic and therapeutic ...
Entolimod™ is a novel Toll-like receptor 5 (TLR5) agonist that activates NF-κB signaling pathways to protect cells from damage and stimulate immune responses. Entolimod™ for ARS has received Fast ...
(RTTNews) - Pluri Inc. (PLUR), a biotechnology company specializing in cell-based solutions, announced on Monday that it is assessing its readiness to initiate mass production of PLX-R18, a potential ...
Initial presentation on January 26, 2026 showcased Entolimod's potential to mitigate and prevent both gastrointestinal and hematopoietic injury from ionizing radiation exposure. FREMONT, CA / ACCESS ...
CLAREMONT, Calif.--(BUSINESS WIRE)--Synedgen, Inc., a biotechnology company targeting human glycobiology to treat gastrointestinal diseases, today announced a partnership valued at up to $119 million ...
INDs Transferred from Statera Biopharma Advance Entolimod for ARS Along Regulatory Pathway and Enable Pursuit of Clinical Trial Program in Neutropenia and Lymphocyte Exhaustion FREMONT, ...
Redhill Biopharma Ltd.'s opaganib hydrochloride (ABC-294640) has been selected by the Radiation and Nuclear Countermeasures Program (RNCP), of the National Institute of Allergy and Infectious Diseases ...
FREMONT, CA / ACCESS Newswire / November 18, 2025 / Tivic Health® Systems, Inc. (NASDAQ:TIVC), a late-stage therapeutics company, today announced it has secured an exclusive Techwatch meeting with the ...
HAIFA, Israel, Nov. 25, 2024 (GLOBE NEWSWIRE) -- Pluri Inc. (PLUR) (“Pluri” or the “Company”), a biotechnology company leveraging its proprietary platform for cell-based solutions to create a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results